このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

ProPhase Labs 将来の成長

Future 基準チェック /56

ProPhase Labsは、97.4%と60.9%でそれぞれ年率97.4%で利益と収益が成長すると予測される一方、EPSはgrowで105.1%年率。

主要情報

97.4%

収益成長率

105.1%

EPS成長率

Pharmaceuticals 収益成長	27.6%
収益成長率	60.9%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	13 May 2024

今後の成長に関する最新情報

Recent updates

Does This Valuation Of ProPhase Labs, Inc. (NASDAQ:PRPH) Imply Investors Are Overpaying?

Mar 04

ProPhase Labs, Inc.'s (NASDAQ:PRPH) Business And Shares Still Trailing The Industry

Jan 09

ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate

Sep 21

Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt

Aug 11

We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease

Apr 07

ProPhase Labs to license two investigational cancer compounds from Global BioLife

Jul 21

ProPhase Labs: A Stellar Quarter And Another Special Dividend

May 16

ProPhase Labs (NASDAQ:PRPH) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Apr 08

ProPhase Labs (NASDAQ:PRPH) Is Using Debt Safely

Mar 23

Rock star Growth Puts ProPhase Labs (NASDAQ:PRPH) In A Position To Use Debt

Nov 30

As Employer Vaccine Mandates Fail, Prophase Labs Could Benefit

Oct 20

Calculating The Fair Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)

Jul 22

ProPhase Labs Is A Potential Pure Play On Worries About The Delta And Delta Plus Covid-19 Variants

Jun 28

Here's Why Shareholders May Consider Paying ProPhase Labs, Inc.'s (NASDAQ:PRPH) CEO A Little More

May 14

ProPhase Labs partners with Dutchess County New York to provide COVID-19 testing

May 06

A Look At The Intrinsic Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)

Apr 12

ProPhase Labs opens Covid testing facility in New York

Jan 29

業績と収益の成長予測

NasdaqCM:PRPH - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	197	32	N/A	N/A	1
12/31/2025	138	12	N/A	N/A	1
12/31/2024	47	-17	N/A	N/A	3
3/31/2024	29	-24	-21	-17	N/A
12/31/2023	44	-17	-15	-11	N/A
9/30/2023	63	-10	-14	-10	N/A
6/30/2023	79	-4	-6	-3	N/A
3/31/2023	94	7	5	9	N/A
12/31/2022	123	18	25	29	N/A
9/30/2022	146	31	21	23	N/A
6/30/2022	131	27	13	15	N/A
3/31/2022	111	18	13	15	N/A
12/31/2021	79	6	-18	-14	N/A
9/30/2021	39	-5	-21	-16	N/A
6/30/2021	33	-2	-16	-11	N/A
3/31/2021	28	0	-16	-11	N/A
12/31/2020	15	-2	-4	-3	N/A
9/30/2020	12	-2	3	4	N/A
6/30/2020	11	-2	3	3	N/A
3/31/2020	9	-3	-2	-2	N/A
12/31/2019	10	-3	-1	-1	N/A
9/30/2019	11	-3	-1	-1	N/A
6/30/2019	11	-4	-2	-2	N/A
3/31/2019	12	-3	-1	-1	N/A
12/31/2018	13	-2	-2	-2	N/A
9/30/2018	13	-1	-3	-3	N/A
6/30/2018	14	-1	-2	-2	N/A
3/31/2018	13	-1	-6	-6	N/A
12/31/2017	10	-2	N/A	-3	N/A
9/30/2017	6	-3	N/A	-1	N/A
6/30/2017	5	-3	N/A	-1	N/A
3/31/2017	4	-3	N/A	2	N/A
12/31/2016	4	-4	N/A	0	N/A
9/30/2016	-6	-3	N/A	-2	N/A
6/30/2016	-3	-2	N/A	-4	N/A
3/31/2016	-2	-2	N/A	-5	N/A
12/31/2015	3	-2	N/A	-3	N/A
9/30/2015	21	-3	N/A	-4	N/A
6/30/2015	22	-7	N/A	-3	N/A
3/31/2015	22	-8	N/A	-4	N/A
12/31/2014	22	-8	N/A	-3	N/A
9/30/2014	23	-7	N/A	-1	N/A
6/30/2014	24	-2	N/A	-1	N/A
3/31/2014	24	-1	N/A	0	N/A
12/31/2013	25	0	N/A	1	N/A
9/30/2013	25	0	N/A	-2	N/A
6/30/2013	24	0	N/A	-1	N/A

アナリストによる今後の成長予測

収入対貯蓄率: PRPHは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.4% ) よりも高い成長率であると考えられます。

収益対市場: PRPH今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: PRPH今後 3 年以内に収益を上げることが予想されます。

収益対市場: PRPHの収益 ( 60.9% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: PRPHの収益 ( 60.9% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: PRPHの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

ProPhase Labs 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Price target decreased by 7.5% to US$18.50

Consensus revenue estimates fall by 16%

Consensus EPS estimates fall by 46%

Consensus estimates of losses per share improve by 19%

Price target increased by 13% to US$17.00

Consensus forecasts updated

Recent updates

Price target decreased by 7.5% to US$18.50

Insufficient new directors

ProPhase Labs, Inc., Annual General Meeting, Jun 20, 2024

ProPhase Labs, Inc. to Report Q1, 2024 Results on May 09, 2024

ProPhase Labs, Inc. Unveils Project ZenQ-AI

ProPhase Labs, Inc. announced delayed annual 10-K filing

ProPhase Labs, Inc. to Report Fiscal Year 2023 Results on Mar 15, 2024

Does This Valuation Of ProPhase Labs, Inc. (NASDAQ:PRPH) Imply Investors Are Overpaying?

Prophase Labs, Inc. Announces Important Developments in the Company’s Efforts to Commercialize Its Novel Be-Smart Esophageal Cancer Diagnostic Test

ProPhase Labs, Inc. Announces Preliminary Positive Results for Dietary Supplement Equivir

ProPhase Labs, Inc.'s (NASDAQ:PRPH) Business And Shares Still Trailing The Industry

Consensus revenue estimates fall by 16%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

ProPhase Labs, Inc. to Report Q3, 2023 Results on Nov 09, 2023

ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate

Consensus EPS estimates fall by 46%

New minor risk - Market cap size

Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt

First quarter 2023 earnings released: EPS: US$0.033 (vs US$0.81 in 1Q 2022)

Investor sentiment deteriorates as stock falls 15%

ProPhase Labs, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Investor sentiment deteriorates as stock falls 17%

ProPhase Labs, Inc Provides an Update Regarding Its Progress and Development Strategy for Linebacker-1

ProPhase Labs, Inc Provides an Update Regarding Its Progress and Development Strategy for Linebacker-1

Consensus estimates of losses per share improve by 19%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ProPhase Labs, Inc. to Report Q1, 2023 Results on May 11, 2023

Investor sentiment improves as stock rises 18%

Price target increased by 13% to US$17.00

We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 17%

ProPhase Labs, Inc. Provides Update on Linebacker-1 Cancer Co-Therapy Program and Outlines Development Strategy

Chairman & CEO exercised options and sold US$2.0m worth of stock

ProPhase Labs (NASDAQ:PRPH) Seems To Use Debt Quite Sensibly

Chairman & CEO exercised options and sold US$2.8m worth of stock

ProPhase Labs, Inc. (NasdaqCM:PRPH) acquired World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for $4.6 million.

ProPhase Labs, Inc. Announces Executive Changes

ProPhase Labs, Inc. (NasdaqCM:PRPH) entered into an asset purchase agreement to acquire World-wide exclusive rights to Stella’s BE-Smart Esophageal Pre-Cancer diagnostic screening test from Stella Diagnostics Inc. (OTCPK:SLDX) for approximately $4.5 million.

Consensus forecasts updated

Insufficient new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 23% undervalued after recent price drop

ProPhase Labs, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Investor sentiment improved over the past week

Chairman & CEO exercised options and sold US$3.1m worth of stock

ProPhase Labs: Small Cap Stock With Strong Fundamentals And Growth Potential

ProPhase Labs, Inc. Announces Resignation of Bill White as Chief Financial Officer

Consensus EPS estimates increase by 49%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

ProPhase Labs Q2 2022 Earnings Preview

ProPhase Labs, Inc. to Report Q2, 2022 Results on Aug 11, 2022

ProPhase Labs, Inc. (NasdaqCM:PRPH) announces an Equity Buyback for $6 million worth of its shares.

We Think ProPhase Labs (NASDAQ:PRPH) Can Stay On Top Of Its Debt

Investor sentiment deteriorated over the past week

ProPhase Labs to license two investigational cancer compounds from Global BioLife

Price target increased to US$14.50

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Insufficient new directors

Chairman & CEO exercised options and sold US$1.8m worth of stock

Investor sentiment improved over the past week

Price target decreased to US$13.00

Upcoming dividend of US$0.30 per share

ProPhase Labs: A Stellar Quarter And Another Special Dividend

ProPhase Labs, Inc. Declares Special Cash Dividend, Payable June 3, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

ProPhase Labs, Inc. Announces Chief Financial Officer Changes with Effect from May 23, 2022

ProPhase Labs, Inc. to Report Q1, 2022 Results on May 13, 2022